Catalent Pharma Solutions and UMN Pharma today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent's proprietary GPEx(r) technology. The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines.